Bicycle Therapeutics

Bicycle Therapeutics raising $230m growth capital
Bicycle Therapeutics raising $230m growth capital
Business Weekly
Bicycle Therapeutics
funding
Flag link:
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
BioSpace
Bayer
Bicycle Therapeutics
drug development
radiopharmaceuticals
Flag link:
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B
Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B
BioSpace
Bicycle Therapeutics
Novartis
drug discovery
oncology
radioligand
Flag link:
ASCO-GU – Bicycle tries to put distance between itself and Seagen
ASCO-GU – Bicycle tries to put distance between itself and Seagen
EP Vantage
ASCO-GU
Bicycle Therapeutics
Seagen
Padcev
urothelial cancer
BT8009
Flag link:
Genentech rides up to 2nd target in Bicycle immuno-oncology collab
Genentech rides up to 2nd target in Bicycle immuno-oncology collab
Fierce Biotech
Genentech
Bicycle Therapeutics
Roche
immuno-oncology
Flag link:
AACR 2022 – A weekend of updates yields few winners
AACR 2022 – A weekend of updates yields few winners
EP Vantage
AACR
Bicycle Therapeutics
Rubius Therapeutics
C4 Therapeutics
Zentalis
Affimed
Seagen
Astellas
Flag link:
Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data
Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data
Marketwatch
AACR
Bicycle Therapeutics
clinical trials
urothelial cancer
BT8009
Flag link:
Biopharma’s stock market winners of 2021 revealed
Biopharma’s stock market winners of 2021 revealed
EP Vantage
biotech stocks
Eli Lilly
Pfizer
Abbott Labs
Moderna Therapeutics
Merck KGaA
Novo Nordisk
BioNTech
Biohaven
Prothena
Bicycle Therapeutics
Bellus Health
Evolus
Flag link:
Struggling Ionis licenses Bicycle Therapeutics' platform in a bid to develop drugs that can cross blood-brain barrier
Struggling Ionis licenses Bicycle Therapeutics' platform in a bid to develop drugs that can cross blood-brain barrier
Endpoints
Ionis Pharmaceuticals
Bicycle Therapeutics
blood-brain barrier
drug development
Flag link:
Bicycle Therapeutics announces first patient dosed in phase I dose escalation of BT5528 in combination with nivolumab
Bicycle Therapeutics announces first patient dosed in phase I dose escalation of BT5528 in combination with nivolumab
Pharmaceutical Business Review
Bicycle Therapeutics
clinical trials
BT5528
nivolumab
Flag link:
Genentech pays Bicycle $30M upfront to form discovery-stage immuno-oncology pact
Genentech pays Bicycle $30M upfront to form discovery-stage immuno-oncology pact
Fierce Biotech
Roche
Genentech
Bicycle Therapeutics
R&D
immuno-oncology
Flag link:
Bicycle raises $61M in downsized IPO, joining fellow biotechs on Nasdaq who have hauled in $1.6B collectively
Bicycle raises $61M in downsized IPO, joining fellow biotechs on Nasdaq who have hauled in $1.6B collectively
Endpoints
Bicycle Therapeutics
IPOs
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Incyte
Novartis
Athersys
ResTORbio
Bellerophon Therapeutics
Eli Lilly
CymaBay
Bicycle Therapeutics
Peloton Therapeutics
Ideaya
IPOs
Flag link:
Bicycle Therapeutics Updates Filing for $80 Million IPO
Bicycle Therapeutics Updates Filing for $80 Million IPO
CP Wire
Bicycle Therapeutics
IPOs
drug development
Flag link:
Bicycle Therapeutics Updates Filing for $80 Million IPO
Bicycle Therapeutics
IPOs
Flag link:
Bicycle hires clinical leader ahead of IPO-fueled pipeline push
Bicycle hires clinical leader ahead of IPO-fueled pipeline push
Fierce Biotech
Bicycle Therapeutics
Flag link:
Bicycle files for $86M IPO to fund trials of novel drug conjugates
Bicycle files for $86M IPO to fund trials of novel drug conjugates
Fierce Biotech
Bicycle Therapeutics
IPOs
BT1718
Flag link:
Bicycle Therapeutics Named Best New Drug Developer at World ADC Awards
Bicycle Therapeutics Named Best New Drug Developer at World ADC Awards
CP Wire
Bicycle Therapeutics
BT1718
antibody-drug conjugate
Flag link:
Bicycle Therapeutics Named Best New Drug Developer at World ADC Awards
Bicycle Therapeutics
BT1718
Flag link:
More Good News for Bicycle Therapeutics
More Good News for Bicycle Therapeutics
CP Wire
Bicycle Therapeutics
ThromboGenics
THR-149
vitreo-retinal disorders
Flag link:

Pages